Tempus Digital Pathology vs Vesta
Paige Prostate Detect holds FDA De Novo DEN200080, decided September 21, 2021, and CE-IVDR marking, and Tempus says it cuts reading time by 20%. It has to run on specific scanners and viewers. Paige Predict, Breast Detect and most of the other apps are labeled research use only. The Prostate Grade and Quantify and Perineural Invasion apps are CE-IVDR and RUO, and the FullFocus viewer holds separate 510(k)s, K201005 and K241273. Tempus completed its Paige purchase on August 22, 2025, and its pages show no price.
The BCG claim for Vesta comes from the vendor, which says patients with its biomarker carry twice the risk of not responding. The J Urol and Eur Urol Oncol papers on it carry a Valar affiliation in PubMed. A 2026 multicenter real-world study in Cancers measured changes in management decisions. Tempus sells slide-reading software to a pathology lab with prostate biopsy volume, and the urologist treating the bladder cancer patient is the one who orders Vesta, so each has its own buyer.
Pathology · Reviewed November 2, 2026
Tempus Digital Pathology
by Tempus AI
Digital pathology AI from Paige, now part of Tempus: Paige Prostate Detect (FDA De Novo, CE-IVDR) plus research-use suites.
Vesta
by Valar Labs
Lab test run in a CLIA lab: AI on routine bladder cancer slides predicts BCG response, ordered by urologists.
When to pick each one
Tempus Digital Pathology
- Paige Prostate Detect, FDA De Novo and CE-IVDR
- FullFocus viewer holds two 510(k)s
- Prostate biopsy slide AI for pathology labs
Vesta
- BCG response and recurrence risk scoring for bladder cancer
- Report ordered by the treating urologist
Score
Each row shows points earned of points available under the published rubric.
Tempus Digital Pathology
38of 100
Vesta
16of 100
| Dimension | Tempus Digital Pathology | Vesta | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 0 / 18 | +18 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 0 / 21 | 8.4 / 21 | -8.4 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 12 / 12 | 3 / 12 | +9 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
Tempus Digital Pathology
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price on the Tempus pages. |
Vesta
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
Tempus Digital Pathology
FDA decisions
K241273 (opens in new tab)510(k)2025-01-09
Paige FullFocus
DEN200080 (opens in new tab)De Novo2021-09-21
Paige Prostate Detect
K201005 (opens in new tab)510(k)2020-07-15
Paige FullFocus
Vesta
FDA decisions
No FDA decision cited in our research as of November 2, 2026.
Peer-reviewed
1 PubMed record names Vesta.
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Tempus Digital Pathology | Vesta |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | n/a |
| HQ | US | n/a |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.